期刊
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
卷 17, 期 2, 页码 125-130出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/13651501.2013.779000
关键词
Cardiometabolic risk factors; somatic treatment; severe mental illness; antipsychotics
类别
资金
- AstraZeneca
- Janssen Pharmaceuticals
Objective. The aim of the study was to determine the prevalence of cardiometabolic dysregulations and their somatic treatment regimens in a group of psychiatric patients treated with antipsychotics. Methods. In a naturalistic cohort study, baseline cardiometabolic parameters were measured in 543 outpatients. Aft er one year, a second assessment was performed in 220 patients out of the total sample. In addition, it was investigated whether in patients with somatic comorbidities adequate treatment was prescribed. Results. In this cohort, about half of the patients fulfilled the criteria for metabolic syndrome. Only a limited number of patients, however, received pharmacologic treatment for individual risk factors: About 19% for hypercholesterolemia, 26% for hypertension, and 52% for diabetes. Non-treated patients were significantly younger than treated patients. Follow-up data show that the course of the cardiometabolic parameters can be dynamic. Conclusions. Cardiometabolic risk factors are highly prevalent in psychiatric patients treated with antipsychotic drugs. Unfortunately, adequate treatment of cardiometabolic comorbidity in these relatively young patients is seriously hampered. Thus, specific guidelines for psychiatric patients have to be developed taking into account the high cardiovascular risk at a relatively young age and potential pharmacokinetic interactions between psychotropics and somatic compounds. Moreover, integration of psychiatric and physical health care systems for patients with mental disorders is urgently needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据